Table 4.

Analysis of Altered Expression of DDIT3 and MGMT in Different Disease Stage Considering the Imatinib Resistance Status among the CML Positive Patients

Methylation status	DDIT3 expression						Resistance status
	Chronic	p Value	Accelerated	p Value	Blast	p Value
Unmethylated (UM)	1.6±0.67		1.99± 0.028		1.26± 0.09		Non resistant (homozygous)
	(N=78)	0.636	(N=2)	0.032	(N=3)	0.001
	1.59±0.42		1.56± 0.35		0		Single allele resistant (heterozygous)
	(N=2)		(N=13)
	0		0		0		Resistant (homozygous)
Partially methylated (PM)	0.118±0.15		0		0.28±0.16		Non resistant
	(N=30)	0.001		0.352	(N=3)	0.054	(homozygous)
	0.507±0.38		0.65± 0.42		0.027± 0.00		Single allele resistant (heterozygous)
	(N=13)		(N=19)		(N=1)
	1.10±0.00		1.07± 0.00		0.796± 0.46		Resistant
	(N=1)		(N=1)		(N=7)		(homozygous)
Hyper methylated (HM)	0.0039± 0.001		0		0		Non resistant
	(N=6)	0.03		0.101		0.001	(homozygous)
	0.0073± 0.004		0.008±0.005 (N=6)		0		Single allele resistant (heterozygous)
	(N=3)
	0.002± 0.001		0.585±0.262 (N=5)		0.153±0.323		Resistant
	(N=5)				(N=21)		(homozygous)
MGMT expression
Unmethylated (UM)	2.51±1.51		1.6±0.33		0		Non resistant
	(N=61)	0.1	(N=2)	0.158		0.02	(homozygous)
	1.25±0.55		1.49±0.29		2.22±0.00		Single allele resistant (heterozygous)
	(N=6)		(N=13)		(N=1)
	1.13±0.00		1.12±0.79		0.232±0.65		Resistant
	(N=1)		(N=2)		(N=9)		(homozygous)
Partially methylated (PM)	1.124±0.57		0		0		Non resistant
	(N=41)	0.001		0.001		0.001	(homozygous)
	0.464±0.322		0.375±0.03		0		Single allele resistant (heterozygous)
	(N=10)		(N=21)
	0		0		0.212±0.55		Resistant
					(N=3)		(homozygous)
Hyper methylated (HM)	0.31±0.29		0		0.97± 0.71		Non resistant
	(N=12)	0.084		0.431	(N=6)	0.196	(homozygous)
	0.235±0.02		0.048± 0.08		0		Single allele resistant (heterozygous)
	(N=2)		(N=4)
	0.0038±0.002		0.011± 0.014		0.46± 0.75		Resistant
	(N=5)		(N=4)		(N=11)		(homozygous)

P <0.05 considered significant, One-Way ANNOVA was performed